超越肿瘤学——HPMA 共聚物在非癌症疾病中的应用。
Beyond oncology--application of HPMA copolymers in non-cancerous diseases.
机构信息
Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA.
出版信息
Adv Drug Deliv Rev. 2010 Feb 17;62(2):258-71. doi: 10.1016/j.addr.2009.10.006. Epub 2009 Nov 10.
Abstract
Macromolecular drug conjugates have been developed to improve the efficacy and safety profile of various therapeutic agents for many years. Among them, N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-drug conjugates are the most extensively studied delivery platforms for the effective treatment of cancer. In recent years, the applications of HPMA copolymers for the treatment of a broader range of non-cancerous diseases have also been explored. This review highlights the recent developments in the rational design, synthesis, and evaluation of novel HPMA copolymer-drug conjugates for non-cancerous diseases, such as musculoskeletal diseases, infectious diseases and spinal cord injury. The translation potential of these applications is also briefly discussed.
摘要
多年来，人们一直在开发高分子药物偶联物，以提高各种治疗药物的疗效和安全性。其中，N-(2-羟丙基)甲基丙烯酰胺（HPMA）共聚物-药物偶联物是研究最广泛的用于有效治疗癌症的药物递送平台。近年来，人们还探索了 HPMA 共聚物在治疗更广泛的非癌症疾病中的应用。本文综述了新型 HPMA 共聚物-药物偶联物在非癌症疾病（如肌肉骨骼疾病、传染病和脊髓损伤）中的合理设计、合成和评价方面的最新进展。本文还简要讨论了这些应用的转化潜力。
相似文献
1
Beyond oncology--application of HPMA copolymers in non-cancerous diseases.超越肿瘤学——HPMA 共聚物在非癌症疾病中的应用。
Adv Drug Deliv Rev. 2010 Feb 17;62(2):258-71. doi: 10.1016/j.addr.2009.10.006. Epub 2009 Nov 10.
2
Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations.利用 HPMA 共聚物纳米药物制剂提高联合抗癌疗法的疗效。
Adv Drug Deliv Rev. 2010 Feb 17;62(2):203-30. doi: 10.1016/j.addr.2009.11.028. Epub 2009 Dec 4.
3
Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities.HPMA 共聚物缀合物是否有作为临床有用的纳米药物的未来？对当前现状和未来机遇的批判性综述。
Adv Drug Deliv Rev. 2010 Feb 17;62(2):272-82. doi: 10.1016/j.addr.2009.12.005. Epub 2009 Dec 11.
4
Highly effective anti-tumor nanomedicines based on HPMA copolymer conjugates with pirarubicin prepared by controlled RAFT polymerization.基于 HPMA 共聚物与吡柔比星偶联物的高效抗肿瘤纳米药物，通过可控 RAFT 聚合制备。
Acta Biomater. 2020 Apr 1;106:256-266. doi: 10.1016/j.actbio.2020.02.011. Epub 2020 Feb 11.
5
Tumor targeting by pH-sensitive, biodegradable, cross-linked N-(2-hydroxypropyl) methacrylamide copolymer micelles.pH 敏感、可生物降解、交联的 N-(2-羟丙基)甲基丙烯酰胺共聚物胶束的肿瘤靶向。
Biomaterials. 2014 Aug;35(24):6622-35. doi: 10.1016/j.biomaterials.2014.04.059. Epub 2014 May 10.
6
N-(2-hydroxypropyl)methacrylamide copolymer-6-(3-aminopropyl)-ellipticine conjugates. Synthesis, in vitro, and preliminary in vivo evaluation.N-（2-羟丙基）甲基丙烯酰胺共聚物-6-（3-氨丙基）-玫瑰树碱缀合物。合成、体外及初步体内评估。
Bioconjug Chem. 2001 Sep-Oct;12(5):711-8. doi: 10.1021/bc0001544.
7
Immunogenicity and immunomodulatory properties of HPMA-based polymers.基于 HPMA 的聚合物的免疫原性和免疫调节特性。
Adv Drug Deliv Rev. 2010 Feb 17;62(2):184-91. doi: 10.1016/j.addr.2009.10.005. Epub 2009 Nov 13.
8
HPMA copolymer-cyclic RGD conjugates for tumor targeting.HPMA 共聚物-环 RGD 缀合物用于肿瘤靶向。
Adv Drug Deliv Rev. 2010 Feb 17;62(2):167-83. doi: 10.1016/j.addr.2009.11.027. Epub 2009 Dec 4.
9
HPMA-based polymer therapeutics improve the efficacy of surgery, of radiotherapy and of chemotherapy combinations.基于 HPMA 的聚合物治疗药物可提高手术、放疗和化疗联合治疗的疗效。
Nanomedicine (Lond). 2010 Dec;5(10):1501-23. doi: 10.2217/nnm.10.130.
10
Gold nanorod-mediated hyperthermia enhances the efficacy of HPMA copolymer-90Y conjugates in treatment of prostate tumors.金纳米棒介导的热疗增强了聚（N-（2-羟丙基）甲基丙烯酰胺）共聚物-90钇偶联物治疗前列腺肿瘤的疗效。
Nucl Med Biol. 2014 Mar;41(3):282-9. doi: 10.1016/j.nucmedbio.2013.12.002. Epub 2013 Dec 10.
引用本文的文献
1
Biopolymer-Based Nanomedicine for Cancer Therapy: Opportunities and Challenges.基于生物聚合物的癌症治疗纳米医学：机遇与挑战。
Int J Nanomedicine. 2024 Jul 22;19:7415-7471. doi: 10.2147/IJN.S460047. eCollection 2024.
2
Synthesis, Morphology, and Rheological Evaluation of HPMA (-2-Hydroxypropyl Methacrylamide)-PCL (Polycaprolactone) Conjugates.HPMA（-2-羟丙基甲基丙烯酰胺）-PCL（聚己内酯）共轭物的合成、形态学及流变学评估
ACS Omega. 2021 Oct 26;6(44):29788-29803. doi: 10.1021/acsomega.1c04243. eCollection 2021 Nov 9.
3
Nanotechnology-Based Strategies to Evaluate and Counteract Cancer Metastasis and Neoangiogenesis.基于纳米技术的策略来评估和对抗癌症转移和新生血管形成。
Adv Healthc Mater. 2021 May;10(10):e2002163. doi: 10.1002/adhm.202002163. Epub 2021 Mar 24.
4
Polymer nanomedicines.聚合物纳米药物。
Adv Drug Deliv Rev. 2020;156:40-64. doi: 10.1016/j.addr.2020.07.020. Epub 2020 Jul 28.
5
POLYMERIC BIOMATERIALS AND NANOMEDICINES.高分子生物材料与纳米药物
J Drug Deliv Sci Technol. 2015 Dec 1;30(Pt B):318-330. doi: 10.1016/j.jddst.2015.05.012.
6
In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity.增强疫苗免疫原性的聚合物连接的Toll样受体激动剂的体内物理化学性质表征。
Nat Biotechnol. 2015 Nov;33(11):1201-10. doi: 10.1038/nbt.3371. Epub 2015 Oct 26.
7
Macromolecular therapeutics.大分子疗法
J Control Release. 2014 Sep 28;190:288-303. doi: 10.1016/j.jconrel.2014.04.013. Epub 2014 Apr 18.
8
Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes.用于炎症性关节炎的纳米药物：含糖皮质激素的聚合物、胶束和脂质体的头对头比较。
ACS Nano. 2014 Jan 28;8(1):458-466. doi: 10.1021/nn4048205. Epub 2013 Dec 27.
9
Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications.纳米医学的最新进展：治疗、诊断和治疗应用。
Curr Opin Biotechnol. 2013 Dec;24(6):1159-66. doi: 10.1016/j.copbio.2013.02.020. Epub 2013 Apr 9.
10
Polymer-drug conjugates: origins, progress to date and future directions.聚合物-药物偶联物：起源、至今的进展和未来方向。
Adv Drug Deliv Rev. 2013 Jan;65(1):49-59. doi: 10.1016/j.addr.2012.10.014. Epub 2012 Nov 2.
本文引用的文献
1
Branched polymer-protein conjugates made from mid-chain-functional P(HPMA).支化聚合物-蛋白质偶联物由中链功能化 P(HPMA)制成。
Biomacromolecules. 2009 Oct 12;10(10):2847-51. doi: 10.1021/bm900678r.
2
Cathepsin K inhibitors for osteoporosis and potential off-target effects.组织蛋白酶 K 抑制剂治疗骨质疏松症及其潜在的非靶标作用。
Expert Opin Investig Drugs. 2009 May;18(5):585-600. doi: 10.1517/13543780902832661.
3
Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics.使用联合聚合物疗法靶向血管生成依赖性钙化肿瘤。
PLoS One. 2009;4(4):e5233. doi: 10.1371/journal.pone.0005233. Epub 2009 Apr 21.
4
Wnt therapy for bone loss: golden goose or Trojan horse?用于骨质流失的Wnt疗法：金鹅还是特洛伊木马？
J Clin Invest. 2009 Apr;119(4):758-60. doi: 10.1172/jci38973.
5
Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice.Wnt抑制因子1在人类骨肉瘤中发生表观遗传沉默，其靶向破坏会加速小鼠骨肉瘤的发生。
J Clin Invest. 2009 Apr;119(4):837-51. doi: 10.1172/JCI37175. Epub 2009 Mar 23.
6
N-(2-hydroxypropyl)methacrylamide-amphotericin B (HPMA-AmB) copolymer conjugates as antileishmanial agents.N-（2-羟丙基）甲基丙烯酰胺-两性霉素B（HPMA-AmB）共聚物缀合物作为抗利什曼原虫药物。
Int J Antimicrob Agents. 2009 May;33(5):441-8. doi: 10.1016/j.ijantimicag.2008.10.013. Epub 2008 Dec 20.
7
Feasibility of using a bone-targeted, macromolecular delivery system coupled with prostaglandin E(1) to promote bone formation in aged, estrogen-deficient rats.使用骨靶向大分子递送系统联合前列腺素E(1)促进老年雌激素缺乏大鼠骨形成的可行性。
Pharm Res. 2008 Dec;25(12):2889-95. doi: 10.1007/s11095-008-9706-0. Epub 2008 Aug 29.
8
Synthesis and evaluation of a well-defined HPMA copolymer-dexamethasone conjugate for effective treatment of rheumatoid arthritis.一种用于有效治疗类风湿性关节炎的明确的HPMA共聚物-地塞米松共轭物的合成与评价
Pharm Res. 2008 Dec;25(12):2910-9. doi: 10.1007/s11095-008-9683-3. Epub 2008 Jul 23.
9
Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates.骨靶向N-（2-羟丙基）甲基丙烯酰胺共聚物-阿仑膦酸盐偶联物的生物分布及药代动力学研究
Mol Pharm. 2008 Jul-Aug;5(4):548-58. doi: 10.1021/mp800003u. Epub 2008 May 28.
10
Biomaterials for the central nervous system.用于中枢神经系统的生物材料。
J R Soc Interface. 2008 Sep 6;5(26):957-75. doi: 10.1098/rsif.2008.0071.
Zotero 插件